Marketed By
zydus
Pack of
1 vial(s) of 5ml
Salt Composition
Pegaspargase Injection
Storage
Keep in cold place
₹17000₹24618
30.94% Off
Tax: ₹850
1
Asviia 3750 IU Injection
Delivering To: —
Indication
blood cancer
Description
Asviia 3750 IU Injection is a chemotherapy injection that shares some characteristics with targeted therapy. Doctor prescribed this medication as a first line therapy for treatment of acute lymphoblastic leukemia (ALL) and other blood cancers. The medicine works by specifically targeting cancer cells and interfering with their growth and survival rate of tumor. Its active ingredient is Pegaspargase Injection belongs to the class of enzyme anti-cancer agents. Strict medical supervision is needed while the medication is taken.
Uses
Acute lymphoblastic leukemia (ALL)
Common side effects
Asviia 3750 IU Injection is an anti-cancer medication. It shows various side effects like other medications have. Consult the doctor if the symptoms persist:
● Diarrhea
● Fatigue
● Loss of appetite
● Headache
● Fever or chills
● Muscle or joint pain
● Anaphylaxis (severe allergic reaction)
● Thrombosis (blood clots)
● Hemorrhage (bleeding)
● Fever or chills
● Muscle or joint pain
● Rash or itching
● Swelling or redness at the injection site
How to use
Asviia 3750 IU Injection should be taken with or without food at the fixed time everyday. The injection is typically administered under the supervision of a healthcare expert. Do not miss or stop the dose without consulting the doctor, as consistent treatment is crucial for its effectiveness.
How it works
Asviia Injection contains an active drug called pegaspargase, an enzyme that breaks down asparagine. Cancer cells particularly leukemia and lymphoma cells cannot produce asparagine on their own. So the medicine deprives them of these essential nutrients thereby stopping their growth of cancer cells in the body.
Safety advice
Alcohol
unsafe
Doctor’s avoid alcohol while taking Asviia 3750 IU Injection as it harms the effectiveness of the treatment and increase the risk of side effects.
Driving
caution
Asviia 3750 IU Injectioncontains dizziness and sleepiness; do not drive while taking the medication
Pregnancy
unsafe
Pregnant women should avoid Asviia 3750 IU Injection a it harms the fetus and may cause complications during pregnancy.
Breast Feeding
unsafe
Asviia 3750 IU Injection is unsafe during breastfeeding; reports suggest the drug may harm the baby.
Kidney
caution
Asviia 3750 IU Injection is not prescribed for kidney patients, as it may worsen kidney function or lead to complications, take a prescription from a healthcare provider.
Liver
unsafe
Asviia 3750 IU Injection is unsafe for liver patients, as it can cause serious liver damage and worsen existing liver conditions, consult the doctor before use it.
FAQs
Asviia 3750 IU Injection treats blood cancer by blocking the. Take a prescription at once before using the medication to ensure safe and effectiveness of the treatment.
Ahabir 500mg tablet is a chemotherapy medication and a form of targeted therapy.
Asviia 3750 IU Injection does not permanently cure blood cancer but helps to stop the production of cancer cells and protect the body from further growing tumor in the body.
Asviia 3750 IU Injection show common side effects, some patient may experience severe symptoms as well. Visit the if the symptoms persist.
Asviia 3750 IU Injection dosage and duration should be taken based on the patient's medical history and the doctor prescription.
Reference
• Guru, F. R., Akhter, R., Bashir, S., Nisar, S. A., Mir, M. H., Zahir, Z., ... & Ara, U. (2024). Efficacy and Safety Profile of Biosimilar Polyethylene Glycol (PEG)-Asparaginase (Asviia) in Patients With Acute Leukemia: A Retrospective Study From Kashmir. Cureus, 16(11).
• Heo, Y. A., Syed, Y. Y., & Keam, S. J. (2019). Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs, 79(7), 767-777.
• Graham, M. L. (2003). Pegaspargase: a review of clinical studies. Advanced drug delivery reviews, 55(10), 1293-1302.
• Ettinger, A. R. (1995). Pegaspargase (oncaspar). Journal of Pediatric Oncology Nursing, 12(1), 46-48.
• Holle, L. M. (1997). Pegaspargase: an alternative?. Annals of Pharmacotherapy, 31(5), 616-624.
Ratings And Reviews
4.57/5
7 Ratings
5 Star
57.14%
4 Star
42.86%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
a year ago
a year ago
View All Reviews
Related Products
MARKETER DETAILS
zydus
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.